Switch to:
Also traded in: Argentina, Brazil, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.64
BMY's Cash to Debt is ranked lower than
71% of the 768 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.60 vs. BMY: 0.64 )
Ranked among companies with meaningful Cash to Debt only.
BMY' s Cash to Debt Range Over the Past 10 Years
Min: 0.32  Med: 0.83 Max: 2.26
Current: 0.64
0.32
2.26
Equity to Asset 0.45
BMY's Equity to Asset is ranked lower than
74% of the 708 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. BMY: 0.45 )
Ranked among companies with meaningful Equity to Asset only.
BMY' s Equity to Asset Range Over the Past 10 Years
Min: 0.33  Med: 0.45 Max: 0.55
Current: 0.45
0.33
0.55
Interest Coverage 10.66
BMY's Interest Coverage is ranked lower than
63% of the 468 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.86 vs. BMY: 10.66 )
Ranked among companies with meaningful Interest Coverage only.
BMY' s Interest Coverage Range Over the Past 10 Years
Min: 5.14  Med: 12.82 Max: 45.04
Current: 10.66
5.14
45.04
F-Score: 4
Z-Score: 6.51
M-Score: -1.90
WACC vs ROIC
7.94%
5.70%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 11.09
BMY's Operating margin (%) is ranked higher than
58% of the 712 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.72 vs. BMY: 11.09 )
Ranked among companies with meaningful Operating margin (%) only.
BMY' s Operating margin (%) Range Over the Past 10 Years
Min: 11.41  Med: 18.21 Max: 30.74
Current: 11.09
11.41
30.74
Net-margin (%) 9.31
BMY's Net-margin (%) is ranked higher than
63% of the 714 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.02 vs. BMY: 9.31 )
Ranked among companies with meaningful Net-margin (%) only.
BMY' s Net-margin (%) Range Over the Past 10 Years
Min: 8.85  Med: 14.13 Max: 56.42
Current: 9.31
8.85
56.42
ROE (%) 10.58
BMY's ROE (%) is ranked higher than
63% of the 745 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.02 vs. BMY: 10.58 )
Ranked among companies with meaningful ROE (%) only.
BMY' s ROE (%) Range Over the Past 10 Years
Min: 10.75  Med: 19.06 Max: 78.36
Current: 10.58
10.75
78.36
ROA (%) 4.89
BMY's ROA (%) is ranked higher than
57% of the 772 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.65 vs. BMY: 4.89 )
Ranked among companies with meaningful ROA (%) only.
BMY' s ROA (%) Range Over the Past 10 Years
Min: 4.78  Med: 7.63 Max: 35.08
Current: 4.89
4.78
35.08
ROC (Joel Greenblatt) (%) 51.90
BMY's ROC (Joel Greenblatt) (%) is ranked higher than
85% of the 765 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.79 vs. BMY: 51.90 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BMY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 45.71  Med: 58.73 Max: 155.17
Current: 51.9
45.71
155.17
Revenue Growth (3Y)(%) -1.90
BMY's Revenue Growth (3Y)(%) is ranked lower than
72% of the 605 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. BMY: -1.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BMY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -8.7  Med: 1.40 Max: 10
Current: -1.9
-8.7
10
EBITDA Growth (3Y)(%) -6.10
BMY's EBITDA Growth (3Y)(%) is ranked lower than
75% of the 553 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.20 vs. BMY: -6.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
BMY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -26.8  Med: -5.00 Max: 18.4
Current: -6.1
-26.8
18.4
EPS Growth (3Y)(%) -7.10
BMY's EPS Growth (3Y)(%) is ranked lower than
70% of the 509 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. BMY: -7.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BMY' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -20.1  Med: -4.90 Max: 26.3
Current: -7.1
-20.1
26.3
» BMY's 10-Y Financials

Financials (Next Earnings Date: 2016-07-28)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

BMY Guru Trades in Q3 2015

Joel Greenblatt 21,863 sh (New)
George Soros 5,000 sh (New)
Ray Dalio 19,528 sh (New)
Signature Select Canadian Fund 258,600 sh (New)
John Burbank 401,253 sh (New)
Ken Fisher 61,180 sh (+76.64%)
RS Investment Management 522,650 sh (+48.88%)
Steven Cohen 1,099,000 sh (+29.42%)
Murray Stahl 58,442 sh (+4.61%)
Vanguard Health Care Fund 45,346,149 sh (+3.72%)
Mairs and Power 284,574 sh (+0.56%)
Pioneer Investments 86,973 sh (+0.37%)
Ronald Muhlenkamp 211,750 sh (+0.06%)
Ruane Cunniff 3,670 sh (unchged)
Steven Cohen 1,100,000 sh (unchged)
First Eagle Investment 13,325 sh (unchged)
Kahn Brothers 28,800 sh (unchged)
Jeff Auxier 5,043 sh (unchged)
Dodge & Cox 79,928 sh (-1.24%)
Mario Gabelli 651,417 sh (-4.01%)
T Rowe Price Equity Income Fund 5,512,700 sh (-5.20%)
Jeremy Grantham 5,400 sh (-27.13%)
Paul Tudor Jones 16,320 sh (-36.92%)
» More
Q4 2015

BMY Guru Trades in Q4 2015

Tom Gayner 10,000 sh (New)
Louis Moore Bacon 260,000 sh (New)
John Burbank 1,958,072 sh (+387.99%)
Ray Dalio 70,845 sh (+262.79%)
Pioneer Investments 215,566 sh (+147.85%)
Ken Fisher 134,800 sh (+120.33%)
Steven Cohen 1,264,200 sh (+15.03%)
Vanguard Health Care Fund 46,232,449 sh (+1.95%)
Mairs and Power 287,063 sh (+0.87%)
Jeremy Grantham 5,400 sh (unchged)
Ronald Muhlenkamp 211,755 sh (unchged)
Steven Cohen 117,500 sh (unchged)
Steven Cohen 117,500 sh (unchged)
Ruane Cunniff 3,670 sh (unchged)
Samuel Isaly 1,333,000 sh (unchged)
George Soros Sold Out
Joel Greenblatt Sold Out
RS Investment Management 521,050 sh (-0.31%)
Murray Stahl 57,542 sh (-1.54%)
Mario Gabelli 639,355 sh (-1.85%)
Jeff Auxier 4,943 sh (-1.98%)
Kahn Brothers 28,050 sh (-2.60%)
First Eagle Investment 12,943 sh (-2.87%)
Dodge & Cox 77,458 sh (-3.09%)
T Rowe Price Equity Income Fund 4,520,000 sh (-18.01%)
Paul Tudor Jones 10,400 sh (-36.27%)
» More
Q1 2016

BMY Guru Trades in Q1 2016

Ron Baron 112,848 sh (New)
Ken Fisher 636,060 sh (+371.85%)
Ray Dalio 86,845 sh (+22.58%)
Paul Tudor Jones 11,800 sh (+13.46%)
Pioneer Investments 233,487 sh (+8.31%)
Vanguard Health Care Fund 47,754,809 sh (+3.29%)
Murray Stahl 58,876 sh (+2.32%)
Mario Gabelli 654,005 sh (+2.29%)
Kahn Brothers 28,583 sh (+1.90%)
Jeff Auxier 4,993 sh (+1.01%)
RS Investment Management 526,000 sh (+0.95%)
Ronald Muhlenkamp 212,200 sh (+0.21%)
First Eagle Investment 12,943 sh (unchged)
Tom Gayner 10,000 sh (unchged)
Louis Moore Bacon Sold Out
Ruane Cunniff Sold Out
Mairs and Power 285,918 sh (-0.40%)
Signature Select Canadian Fund 250,300 sh (-3.21%)
Dodge & Cox 73,458 sh (-5.16%)
T Rowe Price Equity Income Fund 4,031,100 sh (-10.82%)
Jeremy Grantham 4,100 sh (-24.07%)
John Burbank 1,374,032 sh (-29.83%)
Steven Cohen 532,100 sh (-57.91%)
Samuel Isaly 1,029,700 sh (-22.75%)
» More
2016

BMY Guru Trades in 2016

Spiros Segalas 8,884,022 sh (+3.04%)
» More
» Details

Insider Trades

Latest Guru Trades with BMY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Bristol-Myers Squibb Company

SymbolPriceYieldDescription
BMYMP1231.900.16$2.00 Convertible Preferred Stock

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:OTCPK:GLAXF, NYSE:SNY, NYSE:ABBV, NYSE:LLY, NYSE:MRK, OTCPK:BAYRY, NYSE:AZN, NYSE:NVS, OTCPK:ALPMY, NYSE:PFE, OTCPK:OTSKF, OTCPK:OPHLY, OTCPK:CHGCF, OTCPK:DSNKY, OTCPK:KYKOF, OTCPK:SNPHY, OTCPK:CHJTF, OTCPK:PTKFF, NAS:ZSPH, NAS:GWPH » details
Traded in other countries:BMY.Argentina, BMYB34.Brazil, BRM.Germany, BMY.Mexico, BMY.Switzerland, 0R1F.UK,
Bristol-Myers Squibb Co is a biopharmaceutical company. It discovers, develops, licenses, manufactures, markets, distributes and sells biopharmaceutical products.

Bristol-Myers Squibb Co is a Delaware corporation and was incorporated in August 1933 under the name Bristol-Myers Company. In 1989, Bristol-Myers Company changed its name to Bristol-Myers Squibb Company as a result of a merger. It is a biopharmaceutical company engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company operates in one segment: Biopharmaceuticals. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and an increasing portion of products produced from biological processes called 'biologics'. These products are sold mainly to wholesalers, and to a lesser extent, directly to distributors, retailers, hospitals, clinics, government agencies and pharmacies. The Company's products include, Plavix, Avapro, Eliquis, Reyataz, Sustiva Franchise, Baraclude, Sprycel, Yervoy, Orencia among others. The Company promotes its products to healthcare providers such as doctors, nurse practitioners, physician assistants, pharmacists, technologists, hospitals, Pharmacy Benefit Managers (PBMs), Managed Care Organizations (MCOs) and government agencies. The Company also markets directly to consumers in the U.S. through direct-to-consumer print, radio and television and digital advertising and promotion. The Company's products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. It manufactures products in the United States (U.S.), Puerto Rico and in six foreign countries. The markets in which the Company competes are generally broad-based and competitive. The Company competes with other research-based drug companies, research companies and generic drug manufacturers. The Company is subject to regulation by regional, country, state and local agencies.

Ratios

vs
industry
vs
history
P/E(ttm) 79.62
BMY's P/E(ttm) is ranked lower than
87% of the 535 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.34 vs. BMY: 79.62 )
Ranked among companies with meaningful P/E(ttm) only.
BMY' s P/E(ttm) Range Over the Past 10 Years
Min: 4.09  Med: 20.58 Max: 79.09
Current: 79.62
4.09
79.09
Forward P/E 29.33
BMY's Forward P/E is ranked lower than
82% of the 65 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.67 vs. BMY: 29.33 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 79.62
BMY's PE(NRI) is ranked lower than
87% of the 533 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.24 vs. BMY: 79.62 )
Ranked among companies with meaningful PE(NRI) only.
BMY' s PE(NRI) Range Over the Past 10 Years
Min: 12.33  Med: 21.95 Max: 79.09
Current: 79.62
12.33
79.09
P/B 8.58
BMY's P/B is ranked lower than
88% of the 734 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.82 vs. BMY: 8.58 )
Ranked among companies with meaningful P/B only.
BMY' s P/B Range Over the Past 10 Years
Min: 2.46  Med: 4.12 Max: 8.53
Current: 8.58
2.46
8.53
P/S 7.33
BMY's P/S is ranked lower than
77% of the 691 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.59 vs. BMY: 7.33 )
Ranked among companies with meaningful P/S only.
BMY' s P/S Range Over the Past 10 Years
Min: 1.63  Med: 2.74 Max: 7.29
Current: 7.33
1.63
7.29
POCF 151.41
BMY's POCF is ranked lower than
96% of the 254 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.49 vs. BMY: 151.41 )
Ranked among companies with meaningful POCF only.
BMY' s POCF Range Over the Past 10 Years
Min: 6.94  Med: 14.57 Max: 150.41
Current: 151.41
6.94
150.41
EV-to-EBIT 51.29
BMY's EV-to-EBIT is ranked lower than
84% of the 526 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.96 vs. BMY: 51.29 )
Ranked among companies with meaningful EV-to-EBIT only.
BMY' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.2  Med: 11.10 Max: 126.7
Current: 51.29
6.2
126.7
EV-to-EBITDA 45.10
BMY's EV-to-EBITDA is ranked lower than
84% of the 557 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.28 vs. BMY: 45.10 )
Ranked among companies with meaningful EV-to-EBITDA only.
BMY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.5  Med: 9.20 Max: 57.3
Current: 45.1
5.5
57.3
Shiller P/E 36.09
BMY's Shiller P/E is ranked higher than
65% of the 149 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 45.12 vs. BMY: 36.09 )
Ranked among companies with meaningful Shiller P/E only.
BMY' s Shiller P/E Range Over the Past 10 Years
Min: 10.83  Med: 16.17 Max: 35.88
Current: 36.09
10.83
35.88
Current Ratio 1.48
BMY's Current Ratio is ranked lower than
73% of the 672 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.40 vs. BMY: 1.48 )
Ranked among companies with meaningful Current Ratio only.
BMY' s Current Ratio Range Over the Past 10 Years
Min: 1.13  Med: 1.61 Max: 2.32
Current: 1.48
1.13
2.32
Quick Ratio 1.30
BMY's Quick Ratio is ranked lower than
64% of the 672 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.78 vs. BMY: 1.30 )
Ranked among companies with meaningful Quick Ratio only.
BMY' s Quick Ratio Range Over the Past 10 Years
Min: 0.93  Med: 1.33 Max: 2.07
Current: 1.3
0.93
2.07
Days Inventory 114.06
BMY's Days Inventory is ranked higher than
50% of the 669 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.06 vs. BMY: 114.06 )
Ranked among companies with meaningful Days Inventory only.
BMY' s Days Inventory Range Over the Past 10 Years
Min: 84.37  Med: 122.43 Max: 141.93
Current: 114.06
84.37
141.93
Days Sales Outstanding 72.59
BMY's Days Sales Outstanding is ranked higher than
51% of the 625 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.75 vs. BMY: 72.59 )
Ranked among companies with meaningful Days Sales Outstanding only.
BMY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 35.38  Med: 64.45 Max: 79.99
Current: 72.59
35.38
79.99
Days Payable 136.90
BMY's Days Payable is ranked higher than
81% of the 586 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.79 vs. BMY: 136.90 )
Ranked among companies with meaningful Days Payable only.
BMY' s Days Payable Range Over the Past 10 Years
Min: 75.93  Med: 141.65 Max: 230.86
Current: 136.9
75.93
230.86

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.04
BMY's Dividend Yield is ranked higher than
62% of the 610 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.62 vs. BMY: 2.04 )
Ranked among companies with meaningful Dividend Yield only.
BMY' s Dividend Yield Range Over the Past 10 Years
Min: 2.04  Med: 4.19 Max: 7.07
Current: 2.04
2.04
7.07
Dividend Payout 1.61
BMY's Dividend Payout is ranked lower than
94% of the 376 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.33 vs. BMY: 1.61 )
Ranked among companies with meaningful Dividend Payout only.
BMY' s Dividend Payout Range Over the Past 10 Years
Min: 0.41  Med: 0.68 Max: 37
Current: 1.61
0.41
37
Dividend Growth (3y) 2.80
BMY's Dividend Growth (3y) is ranked lower than
60% of the 288 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.70 vs. BMY: 2.80 )
Ranked among companies with meaningful Dividend Growth (3y) only.
BMY' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 3.10 Max: 11.4
Current: 2.8
0
11.4
Forward Dividend Yield 2.07
BMY's Forward Dividend Yield is ranked higher than
60% of the 586 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.69 vs. BMY: 2.07 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 2.39
BMY's Yield on cost (5-Year) is ranked higher than
56% of the 707 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.01 vs. BMY: 2.39 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
BMY' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 2.36  Med: 4.83 Max: 8.16
Current: 2.39
2.36
8.16
3-Year Average Share Buyback Ratio -0.60
BMY's 3-Year Average Share Buyback Ratio is ranked higher than
71% of the 424 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.40 vs. BMY: -0.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BMY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.6  Med: 0.60 Max: 5.2
Current: -0.6
-0.6
5.2

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 20.02
BMY's Price/Tangible Book is ranked lower than
94% of the 688 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.38 vs. BMY: 20.02 )
Ranked among companies with meaningful Price/Tangible Book only.
BMY' s Price/Tangible Book Range Over the Past 10 Years
Min: 4.91  Med: 13.80 Max: 53.46
Current: 20.02
4.91
53.46
Price/Projected FCF 2.80
BMY's Price/Projected FCF is ranked lower than
54% of the 303 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.34 vs. BMY: 2.80 )
Ranked among companies with meaningful Price/Projected FCF only.
BMY' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.15  Med: 1.58 Max: 4.53
Current: 2.8
1.15
4.53
Price/Median PS Value 2.66
BMY's Price/Median PS Value is ranked lower than
88% of the 662 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.09 vs. BMY: 2.66 )
Ranked among companies with meaningful Price/Median PS Value only.
BMY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.71  Med: 1.14 Max: 3.13
Current: 2.66
0.71
3.13
Price/Graham Number 8.38
BMY's Price/Graham Number is ranked lower than
93% of the 409 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.09 vs. BMY: 8.38 )
Ranked among companies with meaningful Price/Graham Number only.
BMY' s Price/Graham Number Range Over the Past 10 Years
Min: 1.75  Med: 3.93 Max: 15.06
Current: 8.38
1.75
15.06
Earnings Yield (Greenblatt) (%) 1.99
BMY's Earnings Yield (Greenblatt) (%) is ranked lower than
59% of the 745 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. BMY: 1.99 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BMY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.8  Med: 9.00 Max: 16.1
Current: 1.99
0.8
16.1
Forward Rate of Return (Yacktman) (%) -15.06
BMY's Forward Rate of Return (Yacktman) (%) is ranked lower than
87% of the 326 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.89 vs. BMY: -15.06 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
BMY' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -15.1  Med: 6.15 Max: 26.7
Current: -15.06
-15.1
26.7

More Statistics

Revenue (TTM) (Mil) $16,910
EPS (TTM) $ 0.93
Beta0.91
Short Percentage of Float1.05%
52-Week Range $51.82 - 75.12
Shares Outstanding (Mil)1,669.31

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 18,133 20,676 22,749
EPS ($) 2.50 3.14 3.94
EPS w/o NRI ($) 2.50 3.14 3.94
EPS Growth Rate
(3Y to 5Y Estimate)
19.12%
» More Articles for NYSE:BMY

Headlines

Articles On GuruFocus.com
Baron Funds Comments on Bristol-Myers Squibb May 23 2016 
Baron Funds Comments on Bristol-Myers Squibb Company May 06 2016 
John Burbank Raises Stake in Microsoft Mar 02 2016 
10 Fund Managers Are Totally Wrong on GlaxoSmithKline Jan 26 2016 
5 Top Stocks of the Outperforming Vanguard Health Care Fund Dec 28 2015 
Designing the Appropriate Common Stock Retirement Portfolio: Stock Selection Options Part 1 Sep 14 2015 
Weekly Insider Sells Highlight: IMS, NOW, BMY, EA Aug 11 2015 
Will Bill Ackman Go After Express Scripts Next? Jun 30 2015 
Bristol-Myers Squibb Takes A Step Up On Cancer Drugs, But The Cost Tells A Different Story Jun 22 2015 
Abbvie Inc. Dividend Stock Analysis May 26 2015 

More From Other Websites
5 Low Beta Stocks to Withstand Market Volatility Jul 01 2016
Bristol-Myers, PsiOxus Strike Immuno-Oncology Collaboration Jul 01 2016
Bristol-Myers Squibb and PsiOxus Therapeutics Announce Immuno-Oncology Clinical Collaboration to... Jun 30 2016
7:00 am Bristol-Myers announces collaboration agreement to evaluate PsiOxus' enadenotucirev in... Jun 30 2016
Bristol-Myers Squibb and PsiOxus Therapeutics Announce Immuno-Oncology Clinical Collaboration to... Jun 30 2016
Bristol-Myers Squibb and PsiOxus Therapeutics Announce Immuno-Oncology Clinical Collaboration to... Jun 30 2016
Bristol-Myers Squibb and PsiOxus Therapeutics Announce Immuno-Oncology Clinical Collaboration to... Jun 30 2016
These Large Pharmaceutical Stocks Should be on your Radar Jun 29 2016
Bristol-Myers Trades Ex-Dividend Wednesday (BMY) Jun 29 2016
MEDIA STATEMENT Bristol-Myers Squibb’s Response to ICER’s Draft Scoping Document “Treatment... Jun 29 2016
Life or Death: Why Chinese Patients Mix Drug Cocktails at Home Jun 28 2016
FDA approves first pill to treat all forms of hepatitis C Jun 28 2016
FDA approves first pill to treat all forms of hepatitis C Jun 28 2016
Jim Cramer's 'Mad Money' Recap: 'Brexit' Is the Dumbest Financial Mistake Ever Jun 27 2016
Bristol-Myers Squibb’s Opdivo (nivolumab) Receives Breakthrough Therapy Designation from U.S. Food... Jun 27 2016
Bristol-Myers Squibb's bladder cancer treatment granted breakthrough therapy designation Jun 27 2016
Bristol-Myers Squibb’s Opdivo (nivolumab) Receives Breakthrough Therapy Designation from U.S. Food... Jun 27 2016
The Sky Is Not Falling Jun 26 2016
Sickle Cell Partnership Creates Demonstration Project to Treat Children in Angola Jun 24 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)